Related Experiment Video

Updated: Jun 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Treating dyslipidemia in high-risk patients: case reviews and discussion

Prakash C Deedwania1, Michael H Davidson, Christie M Ballantyne

  • 1Veterans Affairs Medical Center, 2615 E Clinton Ave, San Francisco, CA 93703, USA. deed@ucsfresno.edu

Postgraduate Medicine
|August 12, 2009
PubMed

Insights

Individuals with diabetes and metabolic syndrome are at high risk for coronary heart disease (CHD). Aggressive lipid-lowering treatment, including statins, is crucial for managing cardiovascular risk in these populations.

Area of Science:

  • Cardiology
  • Endocrinology
  • Preventive Medicine

Background:

  • Coronary heart disease (CHD) risk assessment now includes risk equivalents and low-density lipoprotein cholesterol (LDL-C) targets, expanding eligibility for lipid-lowering therapies.
  • Diabetes and metabolic syndrome represent high-risk groups requiring intensive management of multiple cardiovascular risk factors.

Observation:

  • Patients with diabetes benefit from statin therapy for LDL-C reduction and improved lipid profiles, with protective effects comparable to non-diabetic patients.
  • Metabolic syndrome, though not formally a CHD risk equivalent, is associated with significantly elevated cardiovascular risk, necessitating aggressive treatment strategies.
  • Traditional risk assessment tools may be inaccurate for certain populations, such as South Asian immigrants, highlighting challenges in risk stratification.

Findings:

  • Statins effectively lower LDL-C and offer significant cardiovascular protection in diabetic patients.
  • Evidence suggests metabolic syndrome confers a very high CHD risk, warranting aggressive therapeutic interventions.
  • Accurate risk assessment in diverse populations, including immigrants, remains a critical clinical challenge.

Implications:

  • Expanded eligibility criteria for CHD risk reduction therapies benefit high-risk individuals like those with diabetes and metabolic syndrome.
  • Aggressive lipid management is essential for mitigating cardiovascular risk in patients with diabetes and metabolic syndrome.
  • Further research is needed to refine risk assessment tools for diverse ethnic groups and optimize treatment strategies for metabolic syndrome.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...